跳至主要内容
临床试验/NCT00146029
NCT00146029终止不适用

Companion Pharmacogenetic Study to UMCC 9900/9901

University of Michigan Rogel Cancer Center1 个研究点 分布在 1 个国家开始时间: 2005年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
试验地点
1

研究概览

简要总结

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients who participated on UMCC 9900/9901
  • Living patients must give written informed consent

排除标准

  • No tumor block tissue available

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验